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Abstract
The differentiation status of tumor cells, defined by histomorphological criteria, is a prognos-
tic factor for survival of patients affected with intrahepatic cholangiocarcinoma (ICC). To
strengthen the value of morphological differentiation criteria, we wished to correlate histo-
pathological differentiation grade with expression of molecular biliary differentiation markers
and of microRNAs previously shown to be dysregulated in ICC. We analysed a series of
tumors that were histologically classified as well, moderately or poorly differentiated, and
investigated the expression of cytokeratin 7, 19 and 903 (CK7, CK19, CK903), SRY-related
HMG box transcription factors 4 and 9 (SOX4, SOX9), osteopontin (OPN), Hepatocyte
Nuclear Factor-1 beta (HNF1β), Yes-associated protein (YAP), Epithelial cell adhesion mol-
ecule (EPCAM), Mucin 1 (MUC1) and N-cadherin (NCAD) by qRT-PCR and immunostain-
ing, and ofmiR-31,miR-135b,miR-132,miR-200c,miR-221 andmiR-222. Unexpectedly,
except for subcellular location of SOX9 and OPN, no correlation was found between the
expression levels of these molecular markers and histopathological differentiation grade.
Therefore, our data point toward necessary caution when investigating the evolution and
prognosis of ICC on the basis of cell differentiation criteria.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary tumor of the
liver. It represents less than 10% of cholangiocarcinoma cases, but in contrast to perihilar and
distal cholangiocarcinoma, its incidence and mortality rates are rising [1–3]. When evaluating
disease progression, several prognostic factors were proposed. These include tumor size, surgi-
cal strategy, serum markers, TNM staging, histological features, mutational profiles, gene
expression signatures (mRNA, microRNA, lncRNA), or expression of individual genes at the
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mRNA, miRNA or protein level. Prognostic factors can also be evaluated combinatorially, for
instance in the format of nomograms, to improve their prognostic value [4].
Because of its ease of use in the clinic, differentiation of ICC is an often considered prognos-
tic factor. Histopathologically, the proportion of gland formation serves as a differentiation cri-
terium: well-differentiated tumors, which are associated with better survival, exhibit greater
than 95% glandular tissue, moderately differentiated tumors show 50% to 95% gland forma-
tion, and poorly differentiated tumors have less than 50% glandular tissue [5–8]. Interestingly,
a number of markers that qualify as molecular differentiation markers because they were
shown to promote differentiation of cholangiocytes or to be expressed specifically in the biliary
lineage correspond to ICC prognostic factors. One would therefore expect that expression of
molecular differentiation markers would overlap with the prognostic value of ICC. Consis-
tently, Mazur and coworkers found that the transcription factor SRY-related HMG
box transcription factor 9 (SOX9), which is required for bile duct morphogenesis and cholan-
giocyte polarity, is a prognostic factor for survival [7]. Moreover, Terashi et al. showed that
lack of osteopontin (OPN), which is expressed in the cholangiocytes and not in hepatocytes
[9], is associated with poor patient outcome [10]. However, SOX9 was not confirmed as a pre-
dictor of better survival in a different study [11], and not all molecular differentiation markers
have a prognostic value: HNF1β, which is cholangiocyte-specific in adult liver and which stim-
ulates biliary development [12], is not associated with survival rate of ICC [7, 13]. Again, Wang
and coworkers showed that the transcription factor SOX4, which promotes cholangiocyte dif-
ferentiation and bile duct formation [14], is unexpectedly a factor for poor prognosis of ICC
[15].
These observations shed light on a discrepancy between the prognostic value and the
expression of molecular differentiation markers and prompted us to consider that the expres-
sion of molecular markers of cholangiocyte differentiation would have a stronger predicting
value if supported by histopathological differentiation criteria. Here we analysed a cohort of
surgically resected ICCs and verified if histopathological differentiation grade is correlated
with expression of molecular differentiation markers. For the latter, our analysis included tran-
scription factors that are well characterized as differentiation regulators. We also included a set
of microRNAs (miRNAs) which have been shown to be differentially expressed between the
different tumor grades [8]. Indeed, miRNAs are involved in cholangiocarcinoma where they
modulate apoptosis, proliferation, migration and response to therapy [16–19] and several
investigators characterized miRNA expression profiles in ICC to identify miRNA signatures
for improved diagnosis and prognosis [20–24].
Surprisingly, we found that molecular differentiation markers are expressed at similar levels
regardless of the differentiation status of the tumor. Therefore, our data highlight a disparity
between molecular- and histology-based classification and suggest caution when classifying
ICC tumor samples.
Materials and Methods
Ethics Statement
The work on human tissue samples was performed in compliance with the Belgian regulation,
and with the 1975 Declaration of Helsinki. We studied 18 ICCs obtained from 16 patients (12
men; 4 women) surgically treated at the Cliniques Universitaires St Luc (Brussels, Belgium) by
a surgeon who is not co-author of the present paper, prior to the start of the present analysis.
An anonymous registration number was tagged on each sample and researchers who analysed
the samples had no access to the name of the donor. The retrospective analysis of the surgical
specimens was approved by the Commission on Biomedical Ethics of the Université
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Catholique de Louvain and Cliniques Universitaires Saint-Luc (Approval # 2013/08JUL/384).
Informed consent is not required for retrospective analyses.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry for cytokeratin (CK) 7, CK19 and H&E stainings were performed on
4 μm sections of formalin-fixed paraffin-embedded tumors and carried out with a standardized
protocol on a Ventana Benchmark system (Ventana Medical Systems, Tucson, AZ, USA).
Immunofluorescence was performed on 5 μm sections of formalin-fixed paraffin-embedded
tumors. Briefly, tissue sections were deparaffinized and micro-wave heated for 10 min in 10
mM sodium citrate pH 6.0 for antigen unmasking. Sections were permeabilized for 5 min in
phosphate-buffered saline (PBS)/0.3% Triton X-100 before blocking for 45 min in 0.3% milk/
10% bovine serum albumin/0.3% Triton X-100 in PBS. Primary and secondary antibodies
(listed in S1 Table) were diluted in blocking solution and incubated respectively at 4°C over-
night and room temperature for 1 h. Pictures were taken with an Axiovert 200 fluorescent
microscope using AxioVision system.
RNA extraction and RT-qPCR
Formalin-fixed paraffin-embedded tumors were sectioned at 10 μm and regions of interest
were scraped from the glass slides with a surgical blade. Total RNA was isolated using the Reco-
verAll Total Nucleic Acid Isolation Kit for FFPE (#AM1975, Ambion). The procedure included
a crosslink reversal step during RNA isolation and the use of random hexamers and short
amplicon size for the RT-qPCR step [25]. cDNA synthesis was performed with MMLV reverse
transcriptase (#28025–13, Invitrogen) according to manufacturer’s protocol. Gene expression
was quantified by qPCR using Kapa SYBR Fast 2X Universal Master Mix (#KK4601, Sopa-
chem). The primers are listed in S2 Table. For measuring microRNA expression, specific stem-
loop primers were used for reverse transcription and RT-qPCR was performed using a specific
forward primer and a common universal reverse primer (S3 Table). mRNA and microRNA
levels were normalized for β-ACTIN and for means of RNU6 and RNU1a respectively. mRNA
and miRNA could be compared between tumor and non-tumor samples: mean Ct values for β-
ACTIN were 20.21 and 21.70 in tumor and non-tumor, respectively; mean Ct values for means
of U6 and U1A were 15.19 and 16.37 in tumor and non-tumor tissue.
Results
Selection of tumor samples
We histologically classified 18 ICC samples from 16 patients (12 men and 4 women; age 39–75,
mean: 60.2) as well (containing 95% glandular tissue), moderately (50% to 95% gland forma-
tion) or poorly differentiated (less than 50% glandular tissue) (Fig 1A–1C). None of the
patients were receiving treatment, except for one of the two patients with a recurrence and who
was treated with Gemcitabine. In one patient, the ICC contained both a well and a poorly dif-
ferentiated area that were analysed separately. Two patients experienced a recurrence and each
second tumor was also studied separately, leading to a total number of 19 samples of ICC char-
acterized for their histological differentiation. We selected tumors areas in which CK7-positive
cells represented more than 50% of the tumor surface (Fig 1D–1F), in order to reduce the con-
tamination of epithelial cancer cells by non-epithelial cells during the RNA extraction proce-
dure (see below). Tumor characteristics are described in Table 1.
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Molecular differentiation markers in ICC: mRNA and microRNA
expression
To look for a potential correlation between histopathological differentiation grade and molecu-
lar differentiation markers in ICC, we measured the expression of the latter in the tumor
Fig 1. Tumor classification and selection of tumor areas with high density ofCK7+ cells. (A-C) Tumors were classified as well-, moderately- and
poorly-differentiated. (D-F) Immunohistochemical detection of CK7 in representative histologically-graded ICCs. Areas with at least 50% of CK7 staining
were selected for further RNA extraction and immunofluorescence stainings. White scale bars = 200 μm. Black scale bars = 500 μm
doi:10.1371/journal.pone.0157140.g001
Table 1. Characteristics of tumors samples.
ICC
Size 2–16 cm (mean = 5.9)
Macroscopic type 17 mass forming
1 periductal inﬁltrative
Microscopic differentiation 5 well-differentiated
6 moderately differentiated
6 poorly differentiated
1 with both well and poorly differentiated area
Mucin production 5 present
13 absent
Background liver 3 with cirrhosis
15 without cirrhosis
Pathological stage 4 pT1N0; 2 pT1N1
6 pT2aN0; 1 pT2aN1
2 pT2bN0; 2 pT2bN1
1 pT4N1
doi:10.1371/journal.pone.0157140.t001
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samples. We focused on transcription factors that were shown to be stimulators of biliary dif-
ferentiation. Total RNA was extracted from formalin-fixed paraffin-embedded tissue: ICC tis-
sue was delineated using CK7 and H&E staining in the adjacent sections, and non-tumor CK7-
negative tissue from a distant sample of the same surgical specimen was used as control. We
then measured by qRT-PCR the expression of biliary differentiation markers (SOX4, SOX9,
and HNF1β) and of the hepatocyte marker HNF4α. All biliary markers were expressed at lower
levels in the tumor tissue than in the adjacent non-tumor tissue (Fig 2A).HNF4α was low, con-
firming that the tumor samples were not contaminated with significant levels of hepatocytes.
Importantly, our analysis showed that none of the tested markers correlated with histologi-
cal differentiation grade (Fig 2B). In addition, when the ratio of expression in tumor versus
non-tumor tissue was analysed, again no correlation was found between molecular marker
expression and histological grade of the ICCs (Fig 2C).
Since the transcription factors tested above did not correlate with ICC histological grade, we
measured the expression of other markers (OPN,MUC1, CK903, YAP, EPCAM, NCAD and
CK19) that are known to be biliary-specific and associated with ICC [26–32]. All those markers
were expressed at lower levels in the tumor tissue than in the adjacent non-tumor tissue (Fig
3A). Moreover, as observed previously, we did not found any correlation between the biliary
markers and the histological grade of the tumors (Fig 3B). Again, when considering the ratio of
expression in tumor versus non-tumor tissue, no correlation was found (Fig 3C).
We next investigated the expression of miRNAs in our ICC samples. Several studies have
compared the expression of miRNAs in ICC and control tissue [20–24]. We here analysed
miRNAs that were found to be dysregulated in earlier studies in which control tissue was com-
pared with ICC, and whose dysregulation has been correlated with histological differentiation
grade of ICCs (Table 2) [8].
Fig 4A shows that a subset of microRNAs (miR-200c,miR-31 and miR-135b) was expressed
at higher levels in the tumor than in the non-tumor tissue.miR-222 was not detectable in our
ICC samples. When considering differentiation of the tumors, no correlation was found
between histological grade and expression of the selected miRNAs, except formiR-132, which
was low in the poorly differentiated tumors (Fig 4B). However, when considering the ratio of
expression in tumor versus non-tumor tissue, again no correlation was found with histological
grade, even formiR-132 (Fig 4C).
Molecular differentiation markers in ICC—protein expression
Since mRNA expression does not necessarily correlate with protein expression, we analysed
the expression of SOX9, OPN, CK19 and HNF1β by immunostaining on two representative
samples of each histologically-defined differentiation grade (Fig 5). The results showed that the
markers are expressed in the tumors regardless of their differentiation grade. SOX9, which is
normally located in the nucleus, was restricted to the cytoplasm in well-differentiated ICC
while it was expressed in both the cytoplasm and nucleus in moderately and poorly differenti-
ated ICC (Fig 5A–5F). CK19 was expressed in all ICC samples (Fig 5G–5L). Similarly, OPN
was expressed in all tumor types (Fig 5M–5R). However, in well-differentiated ICC, OPN was
predominantly expressed at the apical pole of cells but a subset of cells also displayed cyto-
plasmic location (Fig 5M and 5N, white and yellow arrowheads). In contrast, OPN was
observed mainly in the cytoplasm of cells of moderately differentiated tumors, while only a
subset of cells expressed OPN at the apical pole (Fig 5O and 5P, white and yellow arrowheads).
Poorly differentiated tumors have lost apico-basal polarity, preventing correct interpretation of
polarity marker location. However, in those poorly differentiated tumors some cells expressed
cytoplasmic OPN (Fig 5Q and 5R, yellow arrowheads). Therefore, overall expression of CK19,
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Fig 2. Molecular biliary differentiation markers are not differentially expressed among histologically-
graded iCC's. (A) All biliary differentiation markers are expressed (qRT-PCR) at lower levels in ICC as compared
to distant non-tumoral tissue. Low levels of HNF4α indicate lack of significant contamination with normal
hepatocytes. (Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001). (B-C) Lack of correlation between molecular
differentiation marker expression and tumor grade when comparing (B) ICC samples or (C) the ratio of
expression in tumor versus non-tumor tissue. Dots represent individual ICC samples and horizontal bars
represent the mean of the samples.
doi:10.1371/journal.pone.0157140.g002
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Fig 3. Biliary-specific proteins are not differentially expressed among histologically-graded ICC's. (A) All
markers are expressed (qRT-PCR) at lower levels in ICC as compared to distant non-tumoral tissue.
(Mean ± SEM; *p<0.05, **p<0.01, ***p<0.001). (B-C) Lack of correlation between molecular differentiation
marker expression and tumor grade when comparing (B) ICC samples or (C) the ratio of expression in tumor
versus non-tumor tissue. Dots represent individual ICC samples and horizontal bars represent mean of the
samples.
doi:10.1371/journal.pone.0157140.g003
Differentiation of Intrahepatic Cholangiocarcinoma
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SOX9 and OPN protein does not correlate with histological differentiation grade, but subcellu-
lar location of SOX9 and OPN were related to ICC cell differentiation.
Surprisingly, in contrast to the qRT-PCR data, HNF1β protein expression was high in
poorly differentiated ICC (Fig 5Q–5R and 5Q'–5R') and, low and mislocated, i.e. non-nuclear,
in well differentiated tumors (Fig 5M–5N and 5M'–5N'); moderately differentiated tumors
showed intermediate expression levels (Fig 5O–5P and 5O'–5P').
Discussion
In recent years, many efforts have been devoted to better classify ICCs and determine their
prognosis. Since differentiation grade of the tumors, defined by histopathological criteria, is
closely related to patient outcome [6, 7], in the present work we wished to strengthen histo-
pathological differentiation criteria by correlating them with expression of molecular cholan-
giocyte differentiation markers. We assumed that well differentiated tumors would express
high levels of cholangiocyte markers and that these levels would decrease in less differentiated
tumors. However, our work unexpectedly revealed a lack of correlation between histopatholog-
ical and molecular differentiation criteria in ICC.
Here, we analysed the expression of biliary markers in areas of ICCs where the tumoral cells
(highlighted by the CK7 positive staining) represented more than 50% of the total area in order
to limit contaminations by non-tumor cells. All our carcinoma express low levels of these
markers irrespective of the tumor differentiation grade (Figs 2 to 4), thereby suggesting that
the epithelial cells are undergoing a dedifferentiation process, at least at the molecular level. In
line with this observation, Mazur and coworkers previously proposed that SOX9 expression
decreases in the early step of ICC development [7]. These results raise the question of the real
differentiation status of the tumors, and may explain why some differentiation markers are
associated with good or poor prognosis in distinct studies (e.g. SOX9; [7, 11]), and why some
other differentiation markers such as HNF1β are not associated with prognosis [7, 13].
We further showed by RT-qPCR and immunofluorescence that SOX9 and OPN are
expressed equally in all tumor types (Fig 5). However, their subcellular location depended on
the differentiation grade of the ICC. SOX9 is located in the cytoplasm of well-differentiated
tumors investigated here, whereas it was nuclear or cytoplasmic in moderately and poorly dif-
ferentiated tumors. Cytoplasmic expression of SOX9 has already been observed in pancreatic
adenocarcinoma affected with p53 mutation [34], in breast cancer cells [35] and in biliary tract
cancers [7], suggesting that the location of SOX9 may depend on the mutational status of the
cells. OPN is expressed in the cytoplasm of early biliary progenitors in the embryo, and
becomes apical once the biliary cells become polarized [9]. The dual cytoplasmic and apical
location of OPN found in well-differentiated tumors may reflect distinct levels of molecular
Table 2. Selection of microRNAs associated with ICC differentiation grade.
microRNA Dysregulation in ICC Differential expression between ICC histological-grades[8]
miR-200c Up-[8, 33] or Down-[21, 23] regulated Moderate > Well (FC = 9,6)
miR-221 Up-[8, 33] or Down-[23] regulated Moderate > Well (FC = 4,6)
miR-31 Up-[8, 33] or Down-[23] regulated Moderate >Well (FC = 60,3)
miR-222 Down-regulated[21, 23] Moderate > Well (FC = 4,8)
miR-135b Up-regulated[8, 33] Moderate >Well (FC = 22,7)
miR-132 No Moderate >Well (FC = 15,1)
FC: Fold Change
doi:10.1371/journal.pone.0157140.t002
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Fig 4. ICC-associated microRNAs are not differentially expressed in histologically-graded ICC.MicroRNAs
known to be dysregulated in ICC and differentially expressed among tumor grades were selected for qRT-PCR
analysis. (A) Three microRNAs are up-regulated in ICC when compared to distant non-tumoral tissues.
(Mean ± SEM; *p<0.05). (B-C) Lack of correlation between microRNA expression and tumor differentiation grade
when (B) comparing ICC samples, or (C) when analysing the ratio of expression in tumor versus non-tumor tissue.
Dots represent individual ICC samples.
doi:10.1371/journal.pone.0157140.g004
Differentiation of Intrahepatic Cholangiocarcinoma
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differentiation of the cells within the same tumor. Regarding HNF1β, Mazur and coworkers,
could not correlate HNF1β expression with survival rates of ICC [7]. This is at first sight at
Fig 5. Expression of molecular biliary markers in histologically-graded ICC's. (A-F) SOX9 expression is detected in the cytoplasm of well-
differentiated ICC cells (A-B) and both in the cytoplasm and nucleus of moderately and poorly differentiated tumor cells (C-F). (G-L)CK19 is expressed in
all types of histologically-graded tumors. (M-R)OPN is detected in all types of histologically graded-ICC's. Its expression is mostly apical in well-
differentiated tumor cells (M-N, white arrowheads), but cytoplasmic OPN is detected in moderately and poorly differentiated ICCs and in a subset of well-
differentiated tumor cells (M-R, yellow arrowheads). (M’-R’) HNF1β expression inversely correlates with ICC differentiation grade. White scale
bar = 100 μm, black scale bar = 500 μm.
doi:10.1371/journal.pone.0157140.g005
Differentiation of Intrahepatic Cholangiocarcinoma
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odds with our findings: since we found more HNF1β protein in poorly differentiated tumors,
which are known to be associated with poor prognosis, our data would suggest that HNF1β is a
marker of poor prognosis. However, combining our data with those of Mazur and coworkers
would be in agreement with the overall conclusion of the present work, namely that molecular
differentiation markers do not correlate with histopathological differentiation criteria. Finally,
HNF1β protein expression is higher in poorly differentiated tumors, while HNF1βmRNA does
not correlate differentiation grade. This points toward potential post-transcriptional regulation
and further underscores the care needed when interpreting expression of molecular differentia-
tion markers in ICC.
When analysing our set of tumors, we were unable to corroborate the findings by Plieskatt
and co-workers, who showed thatmiR-200c,miR221,miR-31,miR-135b andmiR-132 are dif-
ferentially expressed between well differentiated, moderately differentiated and papillary carci-
noma-type ICC [8, 33]. In line with this, several groups attempted to list dysregulated
microRNAs in ICCs, but only little overlap can be found when comparing the proposed micro-
RNA lists [8, 21–24, 33]. In addition, contradictory results were found. For instance,miR-200c
was either down-regulated [21, 23] or upregulated [8, 33] (Fig 3). This points towards neces-
sary care when interpreting microRNA expression in ICC. The broad range of control tissue
used to investigate microRNA expression could contribute to the observed discrepancies.
Indeed, control tissues selected by different authors were either normal hepatic bile duct tissue
or total liver parenchyma, which are distinct tissues, and originated from liver associated with
a variety of diseases such as cirrhosis, hepatitis, or infection with Opisthorchis viverrini [8, 33,
36]. In that context, Plieskatt and coworkers showed that in Opisthorchis viverrini-induced
ICC, miRNAs in distal non-tumor tissue clustered closer to the tumor than to non-tumor tis-
sue from control individuals [33]. This is in line with our lack of correlation between miRNA
or mRNA expression and ICC grade when considering the ratio of expression in tumor versus
non-tumor tissue (Fig 3C). Indeed, our controls were from non-tumor tissue taken from the
patient affected with ICC.
Conclusion
In this work we compared histologically-graded ICC rich in epithelial cells and found no corre-
lation between expression of biliary molecular differentiation markers and the histological dif-
ferentiation grade of the tumors. Therefore, our data point towards necessary caution when
classifying ICC tumor samples and determining prognosis based on differentiation criteria.
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